Benign Prostatic Hyperplasia – Epidemiology – Mature Markets

DRG Epidemiology's coverage of BPH comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of BPH for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.

DRG Epidemiology's BPH forecast will answer the following questions:

  • Of all people with BPH, how many in each country across the major mature pharmaceutical markets have been formally diagnosed?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of BPH over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In addition to the total number of cases for each forecast year, DRG Epidemiology also provides at least ten years of forecast data for the following BPH subpopulations:

  • Total prevalent cases by diagnosis status

Note: coverage may vary by country.

Table of contents

  • Benign Prostatic Hyperplasia - Epidemiology - Mature Markets
    • Introduction
      • Key Findings
      • Total Prevalence of Benign Prostatic Hyperplasia per 1,000 Among Males Aged 40+ in 2018 and 2038ttttttttt
      • Relative Sizes of the Factors Contributing to the Trend in Total Prevalent Cases of Benign Prostatic Hyperplasia over the Next Twenty Yearsttttttttt
    • Epidemiology Data
    • Methods
      • Total Incident Cases
      • Total Prevalent Cases of Benign Prostatic Hyperplasia
      • Diagnosed Prevalent Cases of Benign Prostatic Hyperplasia
      • Lifetime DALYs Gained
    • Reference Materials
      • Literature Review
        • Studies Included in the Analysis of Benign Prostatic Hyperplasia
        • Studies Excluded from the Analysis of Benign Prostatic Hyperplasia
      • Risk/Protective Factors
        • Risk/Protective Factors for Benign Prostatic Hyperplasia
      • Bibliography